New Zealand markets open in 4 hours 13 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2100-0.2200 (-6.41%)
As of 11:43AM EST. Market open.

Spruce Biosciences, Inc.

2001 Junipero Serra Boulevard
Suite 640
Daly City, CA 94014
United States
415 655 4168
https://www.sprucebiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees19

Key executives

NameTitlePayExercisedYear born
Mr. Michael G. GreyExec. Chairman14.85kN/A1953
Mr. Samir M. Gharib CPA, CPA, M.B.A.Pres & CFO454.9kN/A1982
Dr. Rosh DiasChief Medical Officer623.44kN/A1968
Dr. Javier Szwarcberg M.D., M.P.H.CEO & DirectorN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Corporate governance

Spruce Biosciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.